Quantcast

Latest Anti-diabetic drug Stories

2010-01-14 20:15:31

Obstructive Sleep Apnea (OSA) adversely affects glucose control in patients with type 2 diabetes, according to a study conducted by researchers at the University of Chicago. The study "demonstrates for the first time that there is a clear, graded, inverse relationship between OSA severity and glucose control in patients with type 2 diabetes," wrote lead author, Renee S. Aronsohn, M.D., instructor of medicine at the University of Chicago. The study also confirmed other reports that undiagnosed...

2009-11-12 11:30:00

NEW YORK, Nov. 12 /PRNewswire/ -- Bob Greene, bestselling author and celebrity trainer, is embracing the message of the World Health Organization and International Diabetes Federation who have designated November 14 as "World Diabetes Day" in hopes of raising diabetes awareness and education globally. Greene follows up his New York Times bestselling books "Total Body Makeover" and "The Best Life Diet" with "THE BEST LIFE GUIDE TO MANAGING DIABETES AND PRE-DIABETES" co-authored by John J....

2009-10-06 06:45:00

Continuous Glucose Monitoring Systems Market to Grow 48% in 2009 VANCOUVER, Oct. 6 /PRNewswire/ - According to a new report series by iData Research, the leading global authority in medical device, dental and pharmaceutical market research, the U.S. market for diabetes drugs, devices and monitoring systems will reach over $55 billion by 2016, tripling in value. The market for insulin will grow over 18% in 2009, while continuous glucose monitoring systems will see growth of 48%. iData's new...

2009-09-29 15:07:09

Diabetes patients should always control their own blood sugar values if this leads to improvements in their treatment. This is the view advocated by Michael Nauck of the Bad Lauterberg Diabetes Center and his coauthors in the current issue of Deutsches Óžrzteblatt International (Dtsch Arztebl Int 2009; 106[37]: 587-94), who discuss sensible approaches to blood glucose self-monitoring. On the basis of their analysis, the authors make differentiated proposals for the...

2009-08-25 10:17:49

Canadian scientists say they have discovered rosiglitazone (Avandia) a type 2 diabetes drug, might be linked with increased risk of heart failure and death. The scientists from the University of Toronto and the Sunnybrook Health Sciences Center in Toronto, said the linkage was found among older patients, compared to a similar drug, pioglitazone (Actos). The scientists used prescription records to identify nearly 40,000 patients aged 66 years and older who started treatment with either...

2009-06-24 08:55:00

Release Highlights - Melogliptin continues to demonstrate potential to be the best-in-class in achieving glycemic control with low incidence of hypoglycemia and neutral effect on body weight - Global Phase III trials likely to start by end 2009 - IND approved by USFDA - Glenmark takes a step closer towards becoming the first Indian company to have a truly global innovative drug for the world In the recently completed 12 week Phase IIb clinical...

32d49103d15144e12ade93e55ba4780d1
2009-06-15 10:00:00

 Promise is held out for the development of novel oral drugs to control blood glucose levels in diabetes patients as the result of research by a Hebrew University of Jerusalem scientist.For his groundbreaking work, Prof. Shlomo Sasson of the Hebrew University School of Pharmacy has been named one of the winners this year of the Hebrew University's Kaye Innovation Awards.Type 2 diabetes is a worldwide epidemic, predicted to affect over 380 million people within the next 20 years. This...

2009-06-10 07:00:00

LOS ALTOS, Calif., June 10 /PRNewswire/ -- InteKrin Therapeutics Inc presented Phase 2a clinical study results at the American Diabetes Association annual meeting in New Orleans demonstrating that once a day oral treatment with INT131 provides anti-diabetic efficacy consistent with maximal dose thiazolidinedione (TZD) therapy but with less hematocrit reduction and weight gain. The 4 week double blind placebo controlled study of INT131 in Type 2 Diabetes Mellitus (T2DM) patients previously...

2009-06-09 08:00:00

- Results Reported at the American Diabetes Association Meeting Validate Mechanistic and Therapeutic Potential of sEH Inhibitor in Treating Type 2 Diabetes - SOUTH SAN FRANCISCO, Calif., June 9 /PRNewswire/ -- Arete Therapeutics Inc. today announced the presentation of three posters that validate the mechanistic activity and therapeutic potential of the company's lead drug candidate, AR9281, an orally-administered soluble epoxide hydrolase (sEH) inhibitor that is in a Phase II clinical...

2009-06-08 17:00:00

- Year-Long Phase 2 Diabetes Study Results Presented at ADA Annual Meeting - NEW ORLEANS, June 8 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, today announced that data from a year-long phase 2 trial (DM-230) evaluating Qnexa(TM) in patients with type 2 diabetes are being highlighted in an oral podium presentation at the American Diabetes...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related